home / stock / vynt / vynt news

VYNT News and Press, Vyant Bio Inc. From 10/27/22

Stock Information
Company Name: Vyant Bio Inc.
Stock Symbol: VYNT
Market: NASDAQ
Website: vyantbio.com
Menu
VYNT VYNT Quote VYNT Short VYNT News VYNT Articles VYNT Message Board
Get VYNT Alerts

News, Short Squeeze, Breakout and More Instantly...
VYNT - Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022

P latform and P oster Presentation s on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWI...
VYNT - Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022

- To Discuss its Novel Drug Discovery Platform that i s A ccelerat ing the P rocess of F inding C ures for N eurogenerative D iseases ...

VYNT - Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series(TM) on Thursday, September 8, 2022

- I nvites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series ™ CHERRY HILL, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (&#x...

VYNT - Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference

CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
VYNT - Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript

Vyant Bio, Inc. (VYNT) Q2 2022 Results Earnings Conference Call August 22, 2022, 04:30 PM ET Company Participants Jay Roberts - President and Chief Executive Officer Andrew LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Confere...

VYNT - Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M

Vyant Bio press release ( NASDAQ: VYNT ): Q2 GAAP EPS of -$0.20. Revenue of $0.17M (-48.5% Y/Y). Cash and cash equivalents totaled $11.7M as of June 30, 2022. For further details see: Vyant Bio GAAP EPS of -$0.20, revenue of $0.17M

VYNT - Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement...
VYNT - Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...

VYNT - Vyant Bio, Inc. (NASDAQ: VYNT) Featured in Coverage of Investor Summit Group's Q3 Virtual Event

Vyant Bio (NASDAQ: VYNT) is an innovative biotechnology company is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (“CNS”) drug discovery platform combin...

VYNT - Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast

CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...
Previous 10 Next 10